KRAS and neoplasm: On the other hand, anti-EGFR agents improved PFS in KRAS wild type tumor affected patients: cetuximab in combination with FOLFIRI and panitumumab with FOLFOX led to an increase of PFS up to 9,9 and 10 months, respectively.